JP2020513814A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513814A5
JP2020513814A5 JP2019550861A JP2019550861A JP2020513814A5 JP 2020513814 A5 JP2020513814 A5 JP 2020513814A5 JP 2019550861 A JP2019550861 A JP 2019550861A JP 2019550861 A JP2019550861 A JP 2019550861A JP 2020513814 A5 JP2020513814 A5 JP 2020513814A5
Authority
JP
Japan
Prior art keywords
viral vector
cas9
composition
antigenic escape
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513814A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022258 external-priority patent/WO2018170015A1/en
Publication of JP2020513814A publication Critical patent/JP2020513814A/ja
Publication of JP2020513814A5 publication Critical patent/JP2020513814A5/ja
Pending legal-status Critical Current

Links

JP2019550861A 2017-03-14 2018-03-13 Crispr cas9免疫ステルス(immune stealth)の操作 Pending JP2020513814A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471267P 2017-03-14 2017-03-14
US62/471,267 2017-03-14
US201862614875P 2018-01-08 2018-01-08
US62/614,875 2018-01-08
PCT/US2018/022258 WO2018170015A1 (en) 2017-03-14 2018-03-13 Engineering crispr cas9 immune stealth

Publications (2)

Publication Number Publication Date
JP2020513814A JP2020513814A (ja) 2020-05-21
JP2020513814A5 true JP2020513814A5 (enExample) 2021-09-02

Family

ID=63522593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550861A Pending JP2020513814A (ja) 2017-03-14 2018-03-13 Crispr cas9免疫ステルス(immune stealth)の操作

Country Status (7)

Country Link
US (1) US11332727B2 (enExample)
EP (1) EP3595694A4 (enExample)
JP (1) JP2020513814A (enExample)
CN (1) CN110913881A (enExample)
GB (1) GB2574561A (enExample)
IL (1) IL268829A (enExample)
WO (1) WO2018170015A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018129368A2 (en) 2017-01-06 2018-07-12 Editas Medicine, Inc. Methods of assessing nuclease cleavage
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN110997908A (zh) 2017-06-09 2020-04-10 爱迪塔斯医药公司 工程化的cas9核酸酶
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
BR112020020266A2 (pt) * 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110499334A (zh) * 2019-08-08 2019-11-26 复旦大学 CRISPR/SlugCas9基因编辑系统及其应用
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
TWI910162B (zh) * 2020-05-05 2026-01-01 美國公爵大學 跨物種相容腺相關病毒組合物及其使用方法
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN115335704A (zh) * 2020-05-12 2022-11-11 隆萨休斯敦股份有限公司 用于检测腺相关病毒的方法和试剂盒
CN113717960B (zh) * 2021-08-27 2023-07-18 电子科技大学 一种新Cas9蛋白、CRISPR-Cas9基因组定向编辑载体及基因组编辑方法
US20260185070A1 (en) * 2022-11-22 2026-07-02 The Regents Of The University Of California CRISPR-Cas Effector Polypeptides, Lipid Nanoparticles, and Methods of Use Thereof
WO2024211456A1 (en) * 2023-04-03 2024-10-10 The Broad Institute, Inc. Engineered type ii cas polynucleotides with reduced immunogenicity and uses thereof
CN117448300B (zh) * 2023-05-08 2024-04-30 珠海舒桐医疗科技有限公司 一种Cas9蛋白、II型CRISPR/Cas9基因编辑系统及应用
AU2024309386A1 (en) 2023-06-30 2025-12-18 Christiana Care Gene Editing Institute, Inc. Nras gene knockout for treatment of cancer
WO2025190256A1 (en) * 2024-03-11 2025-09-18 Geneditbio Limited Type ii cas protein and uses thereof
WO2025213016A2 (en) 2024-04-04 2025-10-09 Christiana Care Gene Editing Institute, Inc. Crispr/cas gene editing of neh4 and/or neh5 domains in nrf2
WO2025226816A1 (en) 2024-04-23 2025-10-30 Christiana Care Gene Editing Institute, Inc. Methods of identifying and correlating crispr-induced exon skipping to phenotypic outcomes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730507B1 (en) * 1993-06-24 2004-05-04 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
CA2441388A1 (en) * 2001-03-20 2002-09-26 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified insulin with reduced immunogenicity
CA2453406A1 (en) * 2001-07-13 2003-01-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for reducing immunogenicity of polypeptides
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US20140271550A1 (en) * 2013-03-14 2014-09-18 The Trustees Of The University Of Pennsylvania Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses
US11136557B2 (en) * 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
KR20250012194A (ko) * 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
CN105517579B (zh) * 2013-07-10 2019-11-15 哈佛大学校长及研究员协会 用于RNA向导的基因调节和编辑的正交Cas9蛋白
WO2015153789A1 (en) * 2014-04-01 2015-10-08 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
ES2730378T3 (es) * 2014-08-27 2019-11-11 Caribou Biosciences Inc Procedimientos para incrementar la eficiencia de la modificación mediada por Cas9

Similar Documents

Publication Publication Date Title
Keeler et al. Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): where are we, and how did we get here?
JP2021511803A5 (enExample)
RU2725813C2 (ru) Векторы, содержащие спейсерные/филлер полинуклеотидные последовательности, и способы их применения
RU2653444C2 (ru) Композиции вектора aav и способы переноса генов в клетки, органы и ткани
AU2026202070A1 (en) Modified AAV capsid polypeptides for treatment of muscular diseases
JP2021512649A5 (enExample)
JP2021534809A (ja) Aavカプシドの向性の再指向化
JP2022508182A5 (enExample)
JP2022525955A (ja) 組換えアデノ随伴ウイルスベクター
JP2019195338A (ja) 標的遺伝子治療のための合成コンビナトリアルaavカプシドライブラリー
JP2020530307A5 (enExample)
US6365403B1 (en) High-efficiency AAV helper functions
KR20160033217A (ko) 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
US20230049066A1 (en) Novel aav3b variants that target human hepatocytes in the liver of humanized mice
AU2018207259A1 (en) Polynucleotides and vectors for the expression of transgenes
TW201629225A (zh) 第九因子基因療法
US20260109979A1 (en) Nucleic acid regulatory elements for gene expression in the liver and methods of use
US20010034062A1 (en) Antibody gene therapy with adeno-associated viral vectors
JP2024519469A5 (enExample)
JP2021520811A5 (enExample)
JP2021531044A5 (enExample)
JP2021500070A5 (enExample)
CN117821513A (zh) 治疗退行性眼部疾病的药物组合物及方法
US11634728B2 (en) Adeno-associated virus (AAV) vector having hybrid HGF gene introduced thereto
CN117867025A (zh) ScAAV-DJ/8装载的精炼凝血因子IX载体的制备及用途